Expression of Nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues

Gongyuan Zhang; Qiao Zhang; Qinxian Zhang; Lei Yin; Shenglei Li; Kuisheng Cheng; Yunhan Zhang; Honghui Xu; Weidong Wu
April 2010
Journal of Cancer Research & Clinical Oncology;Apr2010, Vol. 136 Issue 4, p587
Academic Journal
To determine the expression of nucleostemin (NS), epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) mRNA in human esophageal squamous cell carcinoma (ESCC) tissues and their association in a human ESCC cell line. The expression of NS, EGF and EGFR mRNA was determined in paired normal esophageal and ESCC tissues of 62 patients using in situ hybridization. The association between NS and EGF or EGFR was examined using immunoblotting and real time polymerase chain reaction in a human ESCC cell line transfected with NS siRNA or treated with a selective EGFR inhibitor. In normal esophageal and ESCC tissues, the positive detection rates were 21.0% (13/62) and 69.4% (43/62) for NS mRNA staining, 40.3% (25/62) and 77.4% (48/62) for EGF mRNA staining, and 30.6% (19/62) and 75.8% (41/62) for EGFR mRNA staining, respectively. These results indicated that NS, EGF and EGFR mRNA expression was upregulated mostly in ESCC tissues. Moreover, the expression of NS, EGF and EGFR mRNA was positively correlated with tumor grade, invasion and lymphatic metastasis of ESCC cells. NS mRNA was co-expressed with EGF and EGFR mRNA in ESCC tissues. The in vitro studies using a human ESCC cell line showed that knockdown of NS with NS siRNA significantly reduced EGF and EGFR expression. However, inhibition of the EGFR kinase activity with a specific EGFR kinase inhibitor had minimal effect on NS expression. The upregulation of NS, EGF and EGFR mRNA frequently occurs in ESCC tissues and is associated with malignancy of human esophageal squamous tumors. NS is required for EGF and EGFR expression.


Related Articles

  • Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Rollin, J; Iochmann, S; Bléchet, C; Hubé, F; Régina, S; Guyétant, S; Lemarié, E; Reverdiau, P; Gruel, Y // British Journal of Cancer;2/28/2005, Vol. 92 Issue 4, p775 

    Tissue factor pathway inhibitor-2 (TFPI-2) is a Kunitz-type serine proteinase inhibitor that inhibits plasmin-dependent activation of several metalloproteinases. Downregulation of TFPI-2 could thus enhance the invasive potential of neoplastic cells in several cancers, including lung cancer. In...

  • Downregulation of p57 accelerates the growth and invasion of hepatocellular carcinoma. Guo, Hui; Lv, Yi; Tian, Tao; Hu, Tinghua; Wang, Wenjuan; Sui, Xin; Jiang, Lili; Ruan, Zhiping; Nan, Kejun // Carcinogenesis;Dec2011, Vol. 32 Issue 12, p1897 

    p57 is a multifunctional protein involved in the regulation of tumor formation and development; however, the biological role of p57 in the pathogenesis of hepatocellular carcinoma (HCC) is poorly understood. To explore the role of p57 in the development of HCC, we examined p57 messenger RNA...

  • Detection of circulating tumor cells by nested RT-PCR targeting EGFR/CEA/CK20mRNAs in colorectal carcinoma patients. Teama, Salwa H.; Agwa, Sara H. A. // Egyptian Journal of Medical Human Genetics;2010, Vol. 11 Issue 2, p173 

    Background: EGFR is involved in the epidermal growth factors pathway that regulates cellular processes and is associated with the development of many types of cancer including colorectal cancer. Molecular methods with high sensitivity such as nested polymerase chain reaction (PCR) based assays...

  • The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Memon, A. A.; Sorensen, B. S.; Meldgaard, P.; Fokdal, L.; Thykjaer, T.; Nexo, E. // British Journal of Cancer;6/5/2006, Vol. 94 Issue 11, p1703 

    Increased expression of the epidermal growth factor (EGF) receptors, HER1 and HER2 are related to poor prognosis in most cancers studied. Recently, a high expression of the two remaining receptors of the EGF system, HER3 and HER4 has been related to a favourable prognosis. However, prognostic...

  • mRNA expression of CK19, EGFR and LUNX in patients with lung cancer micrometastasis. XIANSEN ZHANG; JING XIE; CHANGFA YU; LIXIA YAN; ZESHAN YANG // Experimental & Therapeutic Medicine;2014, Vol. 7 Issue 2, p360 

    To evaluate the clinical significance of mRNA expression of cytokeratin 19 (CK19), epidermal growth factor receptor (EGFR) and lung-specific X protein (LUNX), a total of 42 patients who were diagnosed with non-small cell lung cancer (NSCLC) by pathology were studied retrospectively. The...

  • Combined effects of indomethacin and oxaliplatin on lymph node metastasis related factors in human lung cancer xenografts in nude mice. Dan Xing; Yu-Qin Chen; Dong-Chang Wang; Yun-Xia Zhao; Gang Chen // Pakistan Journal of Pharmaceutical Sciences;Nov2016, Vol. 29 Issue 6, p2083 

    To investigate the combined effects of indomethacin and oxaliplatin on expressions of epidermal growth factor receptor (EGFR), E-cadherin (E-cad), intercellular adhesion molecule-1 (ICAM-1) and CD44v6 related to lymph node metastasis of human lung cancer cell lines. Human lung adenocarcinoma...

  • Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Kersting, Christian; Tidow, Nicola; Schmidt, Hartmut; Liedtke, Cornelia; Neumann, Joerg; Boecker, Werner; van Diest, Paul J.; Brandt, Burkhard; Buerger, Horst // Laboratory Investigation (00236837);May2004, Vol. 84 Issue 5, p582 

    The aim of this study was to assess the frequency of egfr whole gene and CA intron repeat amplification in invasive breast cancer as a mechanism for epidermal growth factor receptor (EGFR) protein overexpression. By means of tissue microarrays, protein overexpression and whole gene amplification...

  • Phase II study on lapatinib in advanced EGFR-positive chordoma†. Stacchiotti, S.; Tamborini, E.; Lo Vullo, S.; Bozzi, F.; Messina, A.; Morosi, C.; Casale, A.; Crippa, F.; Conca, E.; Negri, T.; Palassini, E.; Marrari, A.; Palmerini, E.; Mariani, L.; Gronchi, A.; Pilotti, S.; Casali, P.G. // Annals of Oncology;Jul2013, Vol. 24 Issue 7, p1931 

    Background To report on a prospective, investigator-driven, phase II study on lapatinib in epidermal growth factor receptor (EGFR)-positive advanced chordoma patients. Patients and methods From December 2009 to January 2012, 18 advanced progressing chordoma patients entered this study (median...

  • The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer. Al-Batran, S.-E.; Pauligk, C.; Wirtz, R.; Werner, D.; Steinmetz, K.; Homann, N.; Schmalenberg, H.; Hofheinz, R.-D.; Hartmann, J. T.; Atmaca, A.; Altmannsberger, H.-M.; Jäger, E. // Annals of Oncology;Jul2012, Vol. 23 Issue 7, p1699 

    Background The prognostic role of matrix metalloproteinase-9 (MMP-9) in metastatic gastric cancer has not been validated. Patients and methods We carried out a molecular analysis in 222 metastatic gastric cancer patients obtained from clinical trials. We assessed the messenger RNA (mRNA)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics